| Closed |
S1001 |
Phase II Early Stage DLBCL |
7/18/2011 |
6/1/2016 |
100% |
|
|
| Closed |
S1304 |
RPII Dex + High or Low Dose Carfilzomib for R/R MM |
10/18/2013 |
5/15/2016 |
100% |
|
|
| Closed |
S1406 |
Rano Ph II of Irino+Cetuximab +/- Vemurafenib in BRAF mutant mCRC |
11/13/2014 |
4/1/2016 |
100% |
|
|
| Closed |
S0905 |
Ph I / Randomized Ph II Mesothelioma Cediranib |
3/15/2010 |
2/15/2016 |
91% |
|
Published
|
| Closed |
S1400A |
Lung-MAP S1400A: Non-Match, MEDI4736 |
6/15/2014 |
11/18/2015 |
83% |
|
|
| Closed |
S1203 |
PIII 7+3 vs IA vs IA+vorinostat for AML |
12/15/2012 |
11/4/2015 |
96% |
|
|
| Closed |
S1222 |
Ph. III Randomized Trial of fulvestrant +/- exemestane +/- everolimus in HR+ postmenopausal Stage IV |
5/9/2014 |
10/15/2015 |
4% |
|
|
| Closed |
S1202 |
Ph III Study of Duloxetine for AI-associated musculoskleteal symptoms for Early Stage BrCa |
5/15/2013 |
10/1/2015 |
100% |
|
Published
|
| Closed |
S0000B |
SELECT Eye Endpoints (SEE) |
7/1/2004 |
7/31/2015 |
|
|
Published
|
| Closed |
S1310 |
Rando PII GSK1120212 vs 5-FU/Leucovorin or Capecitabine for Refractory Advanced Biliary |
2/15/2014 |
5/15/2015 |
60% |
|
|
| Closed |
S0819 |
Phase III Carbo/Taxol/Bevacizumab +/- Cetuximab in Advanced NSCLC |
7/15/2009 |
5/1/2015 |
78% |
|
Published
|
| Closed |
S1201 |
Phase II Rando Trt Based on ERCC1 for Advanced/Met Gastric Ca or Gastroesophageal Junction (GEJ) Ca |
2/8/2012 |
4/1/2015 |
95% |
|
|
| Closed |
S1400E |
Lung-MAP S1400E: HGF - Rilotumumab plus Erlotinib vs. Erlotinib |
6/15/2014 |
11/25/2014 |
3% |
|
|
| Closed |
S1117 |
Rando PII Aza vs. Aza/Len vs. Aza/Vorin for High Risk MDS and CMML |
3/1/2012 |
11/14/2014 |
100% |
|
Published
|
| Closed |
S0709 |
Phase II Carboplatin/Paclitaxel/Erlotinib vs Erlotinib Alone in Advanced NSCLC |
12/1/2008 |
9/15/2014 |
54% |
|
Published
|
| Closed |
S0812 |
Vitamin D for Premenopausal Women at High Risk for Breast Cancer |
11/1/2011 |
8/15/2014 |
95% |
|
|
| Closed |
S1008 |
Physical activity & dietary change weight loss in breast & colorectal survivors Ph II |
3/1/2012 |
7/1/2014 |
100% |
|
|
| Closed |
S1107 |
Papillary Renal, ARQ 197 +/- Erlotinib, Ph II |
8/20/2012 |
5/29/2014 |
71% |
|
|
| Closed |
S1115 |
Rando Phase II of AZD-6244 add MK-2206 vs mFOLFOX in Pts with Met Pancreatic Cancer After Chemo |
8/15/2012 |
5/15/2014 |
100% |
|
Published
|
| Closed |
S0702 |
CANCER CONTROL: Prospective ONJ Trial |
12/15/2008 |
12/13/2013 |
100% |
|
Published
|
